Glaucoma In Dogs Treatment

What is the best thing to do for my dog’s glaucoma?

Our 8 year old mixed breed dog was diagnosed with glaucoma in June 2007. One eye appears to be completely blind, sensitive to light, and draining. The other eye is showing symptoms of glaucoma now and he seems to be losing his vision completely. I understand that dogs endure a great deal of pain with glaucoma, so I am very concerned about his suffering. He has started losing interest in his favorite activities and he is also whimpering or wincing at times. Our Vet suggested removing the one eye (which is what I also read online as the best treatment), but it will cost nearly $900. We aren’t in a position to pay this kind of money! I feel sad that the only other options seem to be allowing him to suffer or putting him to sleep. Any ideas or advice?

Unfortunately, yes — if you can’t afford to have the eye removed, your dog will live in pain.

Remember that glaucoma involves the swelling of the eyeball, which not only puts pressure on the nerves in/around the eyeball, but puts pressure on the skull, as well. I can only imagine that it feels like a terrible headache, in addition to the tenderness of the eyeball itself.

I had a dog develop glaucoma in both eyes — we removed the first, but when the other one began to swell (despite treatment) the dog completely shut down. He didn’t want to be touched, didn’t want to eat, and was afraid to leave his kennel after he went completely blind. We ended up putting him down…his quality of life had become nonexistent.

Something else you may discuss with your vet. There is an injection they can give to “deaden” the eye if you catch the glaucoma before the eyeball swells too much. It basically hardens and seals off the eye so that it can no longer swell…your dog will be blind (only you can know how that will affect his quality of life, some dogs learn to adjust), but it may be a less expensive option.

Hope this helps, and good luck!

Glaucoma in Dogs and cats

The Cataract Cure: The Russian eye-drop breakthrough: The story of N-acetylcarnosine $7.27 Author Marios Kyriazis brings a wealth of medical expertise to one of the most important breakthroughs in recent times to help combat a disease called “senile cataract”, which affects one in five people over the age of fifty-five. In the past, the only treatment available for this chronic condition was painful and potentially dangerous surgery to remove the cataract. Other treatments are now ava…

Glaucoma $250 An in-depth examination on risk factors, diagnosis, clinical monitoring and treatment of glaucoma

Atlas of Glaucoma $229.95 Glaucoma affects 1% of the population over the age of 40. It is important that the practicing clinician and surgeon recognize both primary and secondary glaucoma and cases associated with other disorders. This lavishly illustrated text is authoritative and presents the reader with the whole spectrum of the disease. The book is divided into three main sections: The Basics of Glaucoma, Clinical Entities, and Treatment of Glaucoma.

Handbook of Glaucoma $99.95 Glaucoma is not a single disease that responds to a single treatment, therefore the diagnosis and treatment of glaucoma is often difficult. The authors of this text have written a clear and concise guide to this not-so-simple disease.

Medical Treatment of Glaucoma $100 Medical Treatment of Glaucoma is the topic of the seventh World Glaucoma Association Consensus. Medical treatment of glaucoma continues to be at the core of glaucoma management. Hence, the results of this report will have broad and significant impact on glaucoma research and clinical practice. The global faculty, consisting of leading authorities on the clinical and scientific aspects of medical management, met in Fort Lauderdale on May 1, 2010 to discuss the reports and refine the consensus statements. As with prior meetings, it was a daunting task to seek and obtain consensus on such a complicated and nuanced subject. It is unclear how each of us decides how we practice, and evidence to guide us often is sparse. Hence, this consensus, as with the others, is based not only on the published literature, but also on expert opinion. Although consensus does not replace and is not a surrogate for scientific investigation, it does provide considerable value, especially when the desired evidence is lacking. The goal of this consensus is to provide a foundation for medical treatment of glaucoma and how it can be best employed in clinical practice. Identification of those areas for which we have little evidence and, therefore, the need for additional research always is a high priority. We hope that this consensus report will serve as a benchmark of our understanding. However, this consensus report, as with each of the others, is intended to be fluid. It is expected that it will be revised and improved with the emergence of new evidence.

The Glaucoma Book $229 Complete evidence-based medical and surgical management of glaucoma for both the general ophthalmologist in practice and residentsThe only book that covers the new generation of glaucoma procedures including trabectome, trabecular bypass and canaloplasty, by the experts who developed themIncludes the latest laser treatments for glaucoma including micro diode and titanium saphire trabeculoplasty as well as laser from an external approachThe most comprehensive coverage of the optic nerve and the importance of nerve fiber layer hemorrhageProvides an integrated approach to neovascular glaucoma merging treatment to the retina, with the use of new anti-VEGF drugs, tubes, and shunts to achieve the best outcomeIntegrates clinical science with basic science to outline the next steps in glaucoma therapy

Glaucoma Surgery $199.95 Filling a gap in the literature, this reference illustrates a wide range of procedures for the treatment of glaucoma and the management of surgical complications-providing clear recommendations from seasoned experts in the field.

Cataract Surgery in the Glaucoma Patient $159 Cataract surgery is one of the most frequently performed procedures in the United States, and cataracts are a leading cause of visual impairment in the world. Glaucoma is also a very common eye disease with an expected 3.3 million Americans afflicted with primary open angle glaucoma by 2020. The coexistence of these two diseases is not uncommon and management of a cataract can have significant impact on the glaucoma status of a patient. Cataract surgery textbooks may have one chapter dedicated to the management of cataract with coexistent glaucoma. Likewise, a typical glaucoma surgical text dedicates one chapter to the management of these two diseases concurrently. This book will focus on the treatment of cataract in the setting of glaucoma, using an evidence-based medicine approach. Managing cataracts to the best advantage of the glaucoma should result in the best visual outcomes for patients. It should be a wonderful resource for general ophthalmologists and residents as well as glaucoma fellows.

Glaucoma: A Patient’s Guide to the Disease $3.95 Primary or chronic open angle glaucoma is a painless condition usually associated with high pressure in the eye. It affects approximately four per cent of all people over the age of fifty. Untreated, glaucoma is a major cause of blindness worldwide. The second edition of Glaucoma: A Patient’s Guide to the Disease, published in 2001, offered essential information about glaucoma and its treatment, presented in a simple question and answer format to allow patients to participate actively in the decision-making process along the road to successful maintenance of their vision. The third edition adds to and augments the previous edition by introducing important updates on new medical and surgical treatments and information on the latest techniques used to diagnose and follow glaucoma. Graham E. Trope provides the answers to dozens of commonly asked questions in sections headed ‘All About Glaucoma’, ‘Tests for Glaucoma’, and ‘All About Treatment’. Also included are discussions of possible complications, detailed illustrations, and a listing of glaucoma societies in Canada, the United States, and United Kingdom. This valuable guide is an essential reference not only for patients but also for all health-care professionals, including general practitioners and optometrists.

Glaucoma Medical Therapy $79.5 Glaucoma medical therapy has evolved with the advent of each new drug. This evolution has moved quickly and generated new information that clinicians need to understand, synthesize, and implement about medications that have specific benefits and risks for their glaucoma patients. This book aims to provide clinicians with an accessible guide to the current art and science of using clinically available drugs for the medical therapy of glaucoma. The contributors have attempted to present evidence-based information, while providing perspective from their clinical experience. In order to reflect the extensive changes that have occurred since the publication of the first edition in 1999, new chapters have been added about fixed combination drugs and the medical treatment of pediatric patients, and existing chapters have been thoroughly revised and updated. Glaucoma Medical Therapy will be a valuable reference for ophthalmologists in both practice and training, as well as for other practitioners who have clinical contact with glaucoma patients.

Techniques in Glaucoma Diagnosis and Treatment $158.93 No Synopsis Available

Glaucoma Update VI $224.64 Glaucoma Update VI comprises the latest progress in scientific glaucomatology. Fortyone articles of highly reputed experts in the field cover the genetics and other risk factors of the disease and provide new insights into the pathophysiology of blood flow, visual function and optic neuropathy in glaucoma. Special emphasis is placed on innovative treatment options, both medical and surgical. Author: Krieglstein, G. K./ Krieglstein, Gunter K. Series Title: Glaucoma Update Binding Type: Hardcover Number of Pages: 271 Publication Date: 1999/09/01 Language: English Dimensions: 9.21 x 6.14 x 0.75 inches

A Patient’s Guide to Glaucoma $24.76 The Patient’s Guide to Glaucoma is a very useful educational resource. The authors have done an excellent job of covering the pertinent aspects of glaucoma from the patient’s perspective. It provides more complete explanations of aspects of glaucoma care than any other presently available resource. It will be very helpful to patients who want more information about medications, laser, trabeculectomy, tube-shunt surgery, and many other subjects. John S. Cohen, MD Director, Glaucoma Service Cincinnati Eye Institute, Volunteer Clinical Professor University of Cincinnati Drs. Kwon, Greenlee and Fingert are to be congratulated for creating this outstanding educational program on glaucoma. These materials provide an excellent overview of the disease and its treatment. The guide can be read in its entirety or searched to answer specific questions. It is aimed at the intelligent patient seeking to understand his or her disease. The ophthalmologist’s best ally in battling glaucoma is a well-informed patient and this guide will serve to develop patients who truly understand their disease. W.L.M. Alward, MD The Frederick C. Blodi Chair in Ophthalmology, Professor of Ophthalmology, Vice-Chair, Dept of Ophthalmology & Visual Sciences, University of Iowa

Angle Closure Glaucoma $128.25 It is a great pleasure and honor to announce that members of the Asian Angle-Closure Glaucoma Club (AACGC) have finally launched the publication of the Angle-Closure Glaucoma textbook. We, the editors of the AACGC, would like to convey our deepest appreciation to the members of the AACGC who dedicated their time and efforts to developing the book, and celebrate this landmark publication in angle-closure glaucoma with all of the members of the AACGC. On October 18, 2001, the AACGC was founded by Chul Hong, Yong Yeon Kim, Ki Ho Park (Korea), Tetsuya Yamamoto (Japan), Prin Rojanapongpun (Thailand), and Kwou-Yeoung Wu (Taiwan), with the aim of playing a leading role in the resolution of prevailing issues related to angle-closure glaucoma in Asian countries. The incidence of angle-closure glaucoma is common throughout Asia, and numerous people have lost their sight as a result. Before the AACGC was established, there had been no sufficient coordination among glaucoma specialists in Asian countries with regard to terminology, classification, and pathophysiology as part of a scholarly effort among glaucoma specialists. On October 18, 2001, a few forward-thinking, young Asian glaucoma specialists took initiatives to set up the AACGC as an Asian-wide scholarly club with the intent of playing a key role in resolving issues related to angle-closure glaucoma. The Organization Committee was soon formed, and it was decided that the first meeting of the AACGC would be held in Seoul, Korea. The Organizing Committee included Advisory Committee members (Dong Ho Youn (Korea), Yoshiaki Kitazawa (Japan), Por-Tying Hung (Taiwan)); Committee members; (President Chul Hong (Korea), Vice-president Tetsuya Yamamoto (Japan), General Secretary Yong Yeon Kim (Korea)); and Scientific Committee members (Ki Ho Park (Korea), Ningli Wang (China), Paul Chew (Singapore), Prin Rojanapongpun (Thailand), Kwou-Yeung Wu (Taiwan), Goji Tomita (Japan), and Tsing-Hong Wang (Taiwan)). The first official meeting of the AACGC was held in Seoul, Korea on November 7-8, 2002, with about 110 Koreans and 27 foreigners attending the meeting to address the characteristics, terminologies, diagnosis, and treatment of angle-closure glaucoma through 33 presentations and subsequent discussions. Professor Chul Hong chaired the meeting. Research papers presented in this first meeting were published under the title Angle-Closure Glaucoma Update 2002 in November 2003, serving as the start of the written history of AACGC. The second meeting was held in Bangkok, Thailand on November 28, 2003 with about thirty attendees, in conjunction with the 19th Asia-Pacific Academy of Ophthalmology. This meeting was chaired by Professor Prin RojanaPongpun. The third meeting was held as a pre-meeting event in Wuhan, China, on September 7 8, 2004 in conjunction with the Annual Meeting of Chinese Ophthalmological Society, with about thirty attendees to address the latest in research activities. Professor Ningli

The Official Patient’s Sourcebook on Glaucoma $28.95 This book has been created for patients who have decided to make education and research an integral part of the treatment process. Although it also gives information useful to doctors, caregivers and other health professionals, it tells patients where and how to look for information covering virtually all topics related to glaucoma (also acute glaucoma; chronic glaucoma; closed angle glaucoma; congenital glaucoma; narrow angle glaucoma; open angle glaucoma), from the essentials to the most advanced areas of research. The title of this book includes the word official. This reflects the fact that the sourcebook draws from public, academic, government, and peer-reviewed research. Selected readings from various agencies are reproduced to give you some of the latest official information available to date on glaucoma. Given patients’ increasing sophistication in using the Internet, abundant references to reliable Internet-based resources are provided throughout this sourcebook. Where possible, guidance is provided on how to obtain free-of-charge, primary research results as well as more detailed information via the Internet. E-book and electronic versions of this sourcebook are fully interactive with each of the Internet sites mentioned (clicking on a hyperlink automatically opens your browser to the site indicated). Hard-copy users of this sourcebook can type cited Web addresses directly into their browsers to obtain access to the corresponding sites. In addition to extensive references accessible via the Internet, chapters include glossaries of technical or uncommon terms.

Classic Papers in Glaucoma $182.25 At the beginning of the 20th century, our knowledge about glaucoma was truly rudimentary. Since then, it has grown to become a field of its own and, in the past decade, our concepts about its pathogenesis and potential avenues of future therapy have taken a quantum leap forward. It was not until the 1990s that the extent of non-pressure dependent risk factors for glaucoma became widely appreciated. Investigations into the role of ischemia and alternatives to pressure-lowering therapy, such as neuroprotective agents, have become the most recent area of focus. The next generation should see many breakthroughs new means of lowering intra-ocular pressure, genetic manipulation of trabecular function, transplantation, gene transfer therapy, and elimination of distinct anterior segment disorders, which lead to trabecular damage. Reversal of blindness, whether through retinal ganglion cell regeneration or transplantation or artificial eyes, will likely become a reality. This book is a testimony to our origins. It is a compilation of papers which, in retrospect, opened new avenues to the understanding and treatment of glaucoma. In order to be “classic”, articles had to have been published prior to 1988. Each article is preceded by a brief introduction, placing it in the perspective of the times and describing how it affected future work in the field. We hope that this composite of classic papers will allow us to reflect on our past in order to lead us into the future, and that it will give the next generation of glaucomatologists a perspective on the past. R. Ritch and R. Caronia

Angle Closure and Angle Closure Glaucoma $45 This is the third glaucoma consensus held under the auspices of the AIGS. It is anticipated that the discussions and conclusions from this consensus will impact care of patients with Angle Closure and Angle Closure Glaucoma significantly. As with the previous consensus meetings on Glaucoma Diagnosis and Open Angle Glaucoma Surgery, the consensus reports were developed over several months in an interactive internet system. The Consensus faculty, consisting of leading authorities on Angle Closure from throughout the world, met in Fort Lauderdale on May 3, 2006 to discuss the reports and refine the consensus points. Primary Angle-Closure Glaucoma is a leading cause of blindness throughout Asia, and may be more common in European-derived populations than previously recognized. Even though Open-Angle Glaucoma is more common than primary Angle Closure Glaucoma, it has been estimated that nearly half of all glaucoma blindness is due to Angle Closure Glaucoma because it tends to be more severe. Further, an aging population should increase the number of individuals affected by Angle Closure Glaucoma. Clearly, strategies need to be articulated to face this challenge. There has been an explosion of research on Angle Closure and Angle Closure Glaucoma during the past two decades. Ultrasound biomicroscopy provided information about the angle that had been hidden from an observer using only a conventional slit lamp. This had lead to changes in our understanding about the mechanisms of disease as well as our approaches to disease management. Even the basic terminology used to discuss Angle Closure and Angle Closure Glaucoma has changed. Newer instruments, such as anterior segment OCT, now offer the promise of even more detailed assessment of the anterior chamber angle. Nevertheless, our current management of patients with Angle Closure Glaucoma remains similar to what it was decades ago, starting with iridotomy and performing additional surgeries as needed. Trying to determine best practices for Angle Closure and Angle Closure Glaucoma with the rapidly growing literature on the topic is daunting. As with the previous two AIGS consensuses, the Angle Closure Consensus is based on the published literature and expert experience. Although consensus does not replace and is not a surrogate for scientific investigation, it does provide considerable value, in particular, when the desired evidence is lacking. The goal of this consensus was to establish what we know’ and what we need to know’ to better elucidate the mechanisms, and optimal screening and treatment strategies for angle closure. It is expected that this consensus report will serve as a benchmark for our current understanding, and that it will be revised and improved with the emergence of new evidence.

Be Sociable, Share!

•